Companies ›Healthcare ›ODTC.PK

ODTC.PK — OTC Pharmaceuticals

Odonate Inc

$150 000,00

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

-92,8 %

Net margin

—

Debt / equity

0,00

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Odonate Inc is a biopharmaceutical company focused on the development of novel therapeutics for the treatment of cancer, primarily through its proprietary Tumor-Targeted Therapeutics platform.

Business. Odonate Inc (ODTC.PK) is a pharmaceutical company operating within the Healthcare sector. The firm engages in pharmaceutical activities with a product-sale revenue model. Specific details regarding operating segments and geographic presence are not available. The company is listed on the OTC market under the ticker symbol ODTC.PK.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

-92,8 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning ODTC.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to ODTC.PK. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Odonate Inc (ODTC.PK) is a pharmaceutical company operating within the Healthcare sector. The firm engages in pharmaceutical activities with a product-sale revenue model. Specific details regarding operating segments and geographic presence are not available. The company is listed on the OTC market under the ticker symbol ODTC.PK.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

AI synthesis

GENERATED

Odonate Inc has a capital structure characterized by a debt-to-equity ratio of 0.0, indicating no long-term debt obligations, and a current ratio of 5.91, suggesting strong short-term liquidity. The company's total equity of $136.1 million is supported by total assets of $167.9 million, with total liabilities of $31.7 million. Despite this, the company reported negative operating and free cash flows of -$113.1 million and -$126.3 million, respectively, in the latest period.

Profitability metrics for Odonate Inc are negative, with a return on equity of -92.81% and a return on assets of -75.26%. These figures are significantly below the industry median for pharmaceutical companies, which typically report positive returns on equity and assets. The company's net income of -$126.4 million reflects ongoing losses, consistent with its early-stage development focus.

Odonate Inc's revenue is not disclosed in the latest financials, and the company reported $0 in revenue for the most recent period. This suggests that the company is not yet generating commercial revenue and is likely relying on equity financing to fund operations. The absence of revenue concentration data implies that the company is not yet diversified in terms of product or geographic exposure.

The company's growth trajectory is not yet defined in terms of revenue, as it has not yet achieved commercial sales. However, the company is investing in its pipeline, as evidenced by a capital expenditure of -$432,000 in the latest period. Analysts have not provided revenue or earnings estimates for the next fiscal year, indicating uncertainty around the company's future performance.

Risk factors for Odonate Inc include its reliance on equity financing, as it has no long-term debt and a low dilution risk score. However, the company's liquidity risk is rated as low, and no immediate filing-based liquidity or dilution flags were detected. The company has not issued any recent equity, and there are no indications of near-term dilution pressure. Nevertheless, the absence of revenue and ongoing losses pose significant operational risks.

Recent events for Odonate Inc include the continued development of its pipeline, with no significant filings or transcripts indicating major changes in strategy or operations. The company remains in the pre-commercialization phase, and its financial performance is consistent with that of a development-stage biopharmaceutical firm.

Key takeaways

Odonate Inc is a pre-revenue biopharmaceutical company with significant negative cash flows and losses.
The company has no long-term debt and a strong current ratio, but its profitability metrics are severely negative.
No revenue has been reported in the latest period, and the company is not yet generating commercial sales.
The company's risk profile is low in terms of liquidity and dilution, but its operational risks are high due to lack of revenue and ongoing losses.
No immediate dilution or liquidity flags have been detected, but the company's long-term viability depends on successful product development and commercialization.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$150 000,00

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$136.1M

Net cashⓘ

—

Current ratioⓘ

5.9

Debt / equityⓘ

0.0

ROAⓘ

-75.3%

ROEⓘ

-92.8%

Cash conversionⓘ

90.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

ROE-92,8 %Bottom quartile

D/E0,00Above P75

Cash Conv0,90Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income
Return On Assets
net_income / total_assets

Source documents

Odonate Inc Market data — financials · 2026-05-28
Odonate Inc Market data — analyst estimates · 2026-05-28

Ownership & reference

Leadership

Kevin C TangChairman of the Board, Chief Executive Officer

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

ODTC.PKCanonical

OTC · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread